Abstract:1264 Objectives: Integration of cell-membranes-derived nanovehicles with drug cargos and imaging agents holds great potential to revolutionize tumor targeted theranostics, and one of the biggest challenges as well. In addition, accurate in vivo pharmacokinetic understanding of these nanoplatforms is still evasive. Our goal is to develop a nanovehicles based on nanoengineering of cell membranes as a positron emission tomography (PET) trackable carrier for tumor-targeted theranostics. Methods: The multicompartment liposomes (MCLs) are developed by reassembling cancer cell membranes with different amount of Tween-80, and are used to conjugate 89Zr via deferoxamine chelator, and load tetrakis(4-carboxyphenyl) porphyrin (TCPP) for in vivo non-invasive positron emission tomography (PET) imaging and photodynamic therapy (PDT), respectively. The biosafety of MCLs was evaluated by H&E staining of main organs and liver functions marks of treated mice. In vivo metabolize process, biodistribution, and lymph node mapping of MCLs was systematically assessed via PET imaging. The 4T1 tumors model was utilized to confirm the tumor uptake and PDT efficient of MCLs after loading with TCPP.RESULTS: The obtained MCLs appear as a multicompartment nanostructure with a regular spherical morphology and an average diameter of 140 nm. The ratios of Tween-80 micelles to cell membranes was important to form MCLs. Additionally, the obtained MCLs are stable for up to 14 days both in the fetal bovine serum (FBS) and PBS. After conjugation with p-SCN-deferoxamine via the amino groups of proteins on the surface of MCLs, 89Zr labeled Df-MCLs (89Zr-Df-MCL) demonstrated excellent radiochemical stability in different biological media and in vivo. 89Zr-Df-MCL demonstrate efficiently target 4T1 tumors by the enhanced permeability and retention (EPR) effect, and are retained over long-term for efficient and effective PDT, while over 63 %ID of 89Zr-Df-MCL at 72 h p.i. was clearing from the reticuloendothelial system through hepatobiliary excretion. Toxicity evaluation confirmed MCLs do not impose acute or chronic toxicity in intravenously injected mice. Additionally, 89Zr-labeled MCLs are able to execute highly sensitive lymph node mapping, for possible prediction and therapy of tumor metastasis via sentinel lymph nodes (SLNs). Conclusions: The multicompartment liposomes as a PET-trackable tumor-targeted theranostics was developed by fusing cancer cell membrane nano-vesicles with Tween-80 nanomicelles. TCPP, as a model drug, was efficiently loaded in the MCLs and served as a fluorescence imaging and photodynamic agent in 4T1-tumor bearing mice. Thus, the biomimetic 89Zr-DfMCLs could serve as a PET image-guided, cancer-targeting nanoplatforms to enable disease theranostics in the future

Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging

Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates

Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention.

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-64Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy

Radiolabeled AIE Probes As Dual-modality Imaging Agents for PET/NIR-II Fluorescence-Guided Photothermal Therapy

A Proof-of-Concept Study on the Theranostic Potential of 177Lu-Labeled Biocompatible Covalent Polymer Nanoparticles for Cancer Targeted Radionuclide Therapy

A new chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous µPET/CT imaging and radiotherapy

Lu-177-labeled Payloaded Liposome for SPECT/Optical Dual-modality Imaging and Combined Radio- and Chemotherapy in LLC Mice Model

A liposomal radionanoformulation for targeted drug delivery and real time monitoring by radionuclide imaging for HER2 overexpressing cancers

Integrin Αvβ3-Targeted [64cu]cus Nanoparticles for PET/CT Imaging and Photothermal Ablation Therapy.

Diagnostic Radionuclides Labeled on Biomimetic Nanoparticles for Enhanced Follow‐Up Photothermal Therapy of Cancer

Reassembly of cancer cell membranes into nanovehicles as a PET-trackable carrier for tumor-targeted theranostics

Inherently Pet/Ct Dual Modality Imaging Lipid Nanocapsules For Early Detection Of Orthotopic Lung Tumors

Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts.

Development of a new positron emission tomography tracer for targeting tumor angiogenesis: synthesis, small animal imaging, and radiation dosimetry

The Combined Therapeutic Effects of 131Iodine-Labeled Multifunctional Copper Sulfide-Loaded Microspheres in Treating Breast Cancer.

Development of theranostic dual-layered Au-liposome for effective tumor targeting and photothermal therapy

In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles.

64Cu-labeled melanin nanoparticles for PET/CT and radionuclide therapy of tumor.

Theranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imaging.